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Maternal plasma folate impacts differential DNA
methylation in an epigenome-wide meta-analysis
of newborns
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Folate is vital for fetal development. Periconceptional folic acid supplementation and food for-
tiﬁcation are recommended to prevent neural tube defects. Mechanisms whereby periconcep-
tional folate inﬂuences normal development and disease are poorly understood: epigenetics may
be involved. We examine the association between maternal plasma folate during pregnancy and
epigenome-wide DNA methylation using Illumina’s HumanMethyl450 Beadchip in 1,988 new-
borns from two European cohorts. Here we report the combined covariate-adjusted results using
meta-analysis and employ pathway and gene expression analyses. Four-hundred forty-three
CpGs (320 genes) are signiﬁcantly associated with maternal plasma folate levels during preg-
nancy (false discovery rate 5%); 48 are signiﬁcant after Bonferroni correction. Most genes are
not known for folate biology, including APC2, GRM8, SLC16A12, OPCML, PRPH, LHX1, KLK4 and
PRSS21. Some relate to birth defects other than neural tube defects, neurological functions or
varied aspects of embryonic development. These ﬁndings may inform how maternal folate
impacts the developing epigenome and health outcomes in offspring.
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F
olate (vitamin B9) is vital for fetal development. Folic acid
supplementation at 0.4mg per day or higher is recom-
mended worldwide before and in the very early stages of
pregnancy to reduce the incidence of neural tube defects (NTDs).
Over 50 countries have introduced programs to fortify the food
supply with folic acid to increase folate levels in women of
childbearing age1. Rates of NTDs have clearly decreased following
fortiﬁcation2 and there is increasing interest in the possibility that
higher maternal folate prevents additional birth defects including
oral clefts, cardiac defects and others3. A large international trial
has been launched of supplementation with 4mg versus the
standard 0.4mg to attempt to address these questions3.
Other beneﬁcial effects of higher maternal folate levels have
been reported in humans. These include reduced risk of low birth
weight, pre-term delivery, language delay, leukaemia, childhood
brain tumours and autism, although the evidence is inconsis-
tent4,5. In the United States, food fortiﬁcation has led to an
increase in folate intake twice as large as anticipated6, and
therefore concern has been raised about possible adverse effects,
such as cancer in adults, as a result of this population-wide
intervention1. Furthermore, higher folic acid intake during
pregnancy has been associated with an increased risk of
childhood retinoblastoma and early respiratory illness4.
The mechanisms whereby folic acid prevents NTDs and
potentially other birth defects and later health outcomes are
poorly understood7 but could involve epigenetic changes. Folate
is a critical component in the one-carbon metabolism pathway
providing methyl groups for a range of biochemical reactions,
including methylation of DNA8. DNA methylation is an
important epigenetic determinant of gene expression, and
differential methylation has been associated with multiple
diseases9. Periconceptional maternal folate levels may alter
methylation patterns established in utero that are vital for fetal
development, which could impact later health outcomes in the
offspring.
In mouse models, in utero dietary methyl donor supplementa-
tion has been associated with altered methylation patterns and
disease phenotypes4. The brains of human fetuses with NTDs had
lower global methylation compared with controls, which was
positively correlated with maternal folate levels10. With respect to
gene-speciﬁc differential methylation, perinatal folate has also
been associated with differential methylation in speciﬁc imprinted
genes, such as IGF2 and H19, in offspring, but reported
results are inconsistent11. The only published study using a
platform with reasonable genome-wide coverage, the Illlumina
HumanMethyl450 Beadchip (450K), investigated 23 subjects and
reported that folic acid supplementation during pregnancy was
related to differential methylation upstream of the gene ZFP57,
which plays a central role in the regulation and maintenance of
imprinting12.
Some countries, such as Norway and the Netherlands, do not
fortify the food supply with folic acid. These populations may be
particularly useful for examining the biological implications of
periconceptional folic acid supplementation on offspring health,
as greater variability in the dose and the source of folate may exist
compared with fortiﬁed populations.
To better understand the biological implications of folate status
on the developing fetus, we examine the association between
maternal plasma folate during pregnancy and epigenome-wide
differential DNA methylation in newborn cord blood using the
Illumina HumanMethyl450 (450K) Beadchip. We include 1,988
newborns from two European pregnancy cohorts of Caucasian
ancestry, the Norwegian Mother and Child Cohort Study (MoBa),
and the Generation R Study (Generation R). We combine
results using meta-analysis. Secondary pathway analyses and gene
expression analyses are also explored.
Results
Study characteristics. In MoBa participants (N¼ 1,275), mater-
nal plasma folate levels ranged from 1.6 to 53.2 nmol l 1
(mean¼ 11.9). The maternal plasma folate levels in Generation R
(N¼ 713) ranged from 4.1 to 45.3 nmol l 1 (mean¼ 20.3;
Table 1). The mean maternal age wasB30 years for both cohorts.
Approximately, 15% of MoBa mothers and 25% of Generation
R mothers smoked during the pregnancy and over 60% obtained
college or more advanced levels of education in both studies
(Table 1).
Meta-analysis. Our meta-analysis of the association between
maternal plasma folate levels during pregnancy and differential
DNA methylation in newborn cord blood, adjusted for covariates,
resulted in 443 false discovery rate (FDR)-signiﬁcant CpGs
(Benjamini and Hochberg FDR-corrected P (PBH)o0.05; Fig. 1).
Genes with two or more FDR-signiﬁcant CpGs, where at least one
CpG was within the gene, were prioritized for further discussion
(Table 2). Results for all FDR-signiﬁcant CpGs are shown in
Supplementary Data 1 (sorted by the uncorrected P value) and
Supplementary Data 2 (sorted by chromosome and position). The
vast majority of the FDR-signiﬁcant CpGs were robust to
covariate adjustment as well as adjustment for cell type; coefﬁ-
cients from the unadjusted, covariate-adjusted, and covariate- and
cell-type-adjusted models were in the same direction and had a
similar magnitude of effect (Supplementary Data 1 and 2). More
detailed gene information is provided in Supplementary Table 1.
The genomic inﬂation factor (lambda)13 values for the
unadjusted, covariate-adjusted, and covariate- and cell-type-
adjusted models were 0.96, 1.07 and 1.16, respectively
(Supplementary Figs 1–3). Among the 443 FDR-signiﬁcant
CpGs in the covariate-adjusted meta-analysis model, increasing
levels of maternal plasma folate during pregnancy were associated
with decreased methylation of 416 (94%) and increased
methylation of 27 (6%) CpGs. There were 48 CpGs that also
met the strict Bonferroni threshold for statistical signiﬁcance
(Po1.19 10 7, correcting for 419,905 tests). The direction of
effects for the statistically signiﬁcant CpGs was largely consistent
in the MoBa and Generation R populations (Table 2;
Supplementary Data 1 and 2).
Sensitivity analyses. We considered whether vitamin B12, a
co-factor with folate in one-carbon metabolism, contained in
most multivitamins, along with other B vitamins such as B6 and
riboﬂavin, might confound associations between folate and
methylation. Vitamin B12 and folate levels were modestly posi-
tively correlated (Spearman correlation 0.11 in MoBa, 0.14 in
Generation R, Po0.001 for both). When we adjusted for vitamin
B12, the coefﬁcients for folate in relation to methylation changed
only minimally (median change 4.9%, 25–75th percentile
2.3–8.2%, N¼ 1,933 subjects). In addition to the consistency of
effect estimates after adjustment, results remained statistically
signiﬁcant for 376 (85%) at Bonferroni correction for 443
tests, Po1.13 10 4, and all 443 CpGs had Po9 10 4
(Supplementary Data 3). Thus, vitamin B12 does not confound
the folate–methylation associations we observed.
Women with higher folate levels, which largely reﬂect
supplement use, might be more likely to take multivitamins
and/or separate supplements such as cod liver or ﬁsh oils that are
common in Norway. However, vitamin D (total of D2 and D3)
levels were modestly correlated with folate levels (Spearman
correlation coefﬁcient¼ 0.14 in MoBa, 0.23 in Generation R,
Po0.001 for both cohorts). Adjustment for vitamin D only
minimally altered effect estimates for folate in relation to
methylation (median absolute value of change 7.3%, 25–75th
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percentile 3.3–12.3%). Despite the reduction in power due to the
smaller sample size for these adjusted analyses (N¼ 1,664), 70%
of CpGs signiﬁcantly related to folate in the main model
remained Bonferroni signiﬁcant after adjustment for vitamin
D (308 with Po1.13 10 4; Supplementary Data 3).
We performed additional analyses adjusting for two single-
nucleotide polymorphisms (SNPs) in the MTHFR gene that
inﬂuence one-carbon metabolism and are correlated with plasma
folate: rs1801133 and rs1801131 (refs 14,15). These SNPs are in
moderate linkage disequilibrium with each other (r2¼ 0.20–21 in
the two studies). Adjustment for these two SNPs made little
difference in the effect estimates compared with the main model;
median change in coefﬁcient¼ 3.8% (25–75th percentile¼ 2.0–
6.9%) and 85% of CpGs remained statistically signiﬁcant despite
reduction in sample size to 1,880 (Po1.13 10 4, correction for
443 tests). Thus, these genetic variants do not confound the
relationship between folate and methylation.
Homocysteine, unlike folate or vitamin B12, is not a nutrient
that plays a role as a methyl donor or carrier, but is a product
formed during transmethylation in the one-carbon metabolism
cycle. It could be regarded as an intermediate on the causal
pathway between folate and methylation. In addition, like plasma
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Figure 1 | Association between maternal plasma folate and DNA methylation in newborn cord blood: meta-analysis results for MoBa (N¼ 1,275) and
Generation R (N¼ 713) cohorts. The uncorrected –log10(P values) are plotted by CpG genomic position. Multiple testing was accounted for using the false
discovery rate (FDR) procedure by Benjamini and Hochberg. A total of 443 CpGs were considered FDR signiﬁcant (solid horizontal line); 48 CpGs were
also Bonferroni signiﬁcant (dashed horizontal line).
Table 1 | Descriptive characteristics of the MoBa and Generation R study populations.
Variable Category MoBa N (%) Generation R N (%)
Maternal plasma folate (nmol l 1) Min–max 1.6–53.2 4.1–45.3
Mean 11.9 20.3
Median 9.1 19.6
25–75th percentile 6.2–16.0 13.3–26.4
Log-transformed maternal plasma folate Min–max 0.48–4.0 1.4–3.8
Mean 2.3 2.9
Median 2.2 3.0
25–75th percentile 1.8–2.8 2.6–3.3
Maternal age (years) Mean (s.d.) 29.9 (4.3) 31.5 (4.1)
Maternal education level Less than secondary school 96 (7.5) 14 (1.8)
Secondary school completion 415 (32.3) 267 (34.3)
Some college or university 566 (44.1) 203 (26.0)
4 Years or more of college/university 206 (16.1) 296 (37.9)
Missing 6 10
Parity* 0 537 (41.7) 479 (60.7)
1 511 (39.6) 240 (30.4)
2 179 (13.9) 63 (8.0)
3þ 62 (4.8) 7 (0.9)
Missing 0 1
Maternal smoking during pregnancy No 1098 (85.2) 541 (75.6)
Yes 191 (14.8) 175 (24.5)
Missing 0 74
N¼ 1,289 MoBa and N¼ 790 Generation R participants with maternal plasma folate and newborn DNA methylation data. N¼ 1,275 MoBa and N¼ 713 Generation R participants with complete data were
included in the adjusted models.
*Parity was categorized as Z1 versus 0 in the statistical models for the Generation R study.
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folate, it is an excellent marker of folate status. Homocysteine was
strongly correlated with maternal plasma folate in MoBa
(Spearman correlation¼  0.49, Po0.001) and moderately
correlated in Generation R (Spearman correlation¼  0.24,
Po0.001), making it challenging to estimate independent effects.
Given these various factors, inclusion of homocysteine in the
model led to a moderate change in the coefﬁcients for folate in
relation to methylation (median change 10.7%, 25–75th percen-
tile 5.8–17.2%. N¼ 1,931 subjects) and only 137 (31%) CpGs
remained statistically signiﬁcant (Po1.13 10 4, correction for
443 tests).
We also examined whether the associations with methylation
seen for maternal folate levels are also seen for newborn folate
levels in a subset of 572 subjects in Generation R. Thus, this
analysis is not well powered compared with our maternal folate
analysis with 1,988 subjects. However, of the 443 FDR-signiﬁcant
ﬁndings for maternal folate in the meta-analysis there were 60
(14%) with nominal P valueso0.05 for newborn folate which is
higher than the 5% expected by chance alone (Kolmogorov
Po1.2 10 13). This supports the interpretation that some
similar loci are differentially methylated in response to infant
folate, although we were severely underpowered to address this
properly.
Pathway analysis. Pathway analysis with the FDR-signiﬁcant
CpGs showed strong and consistent enrichment of fundamental
development pathways and of neurodevelopmental pathways
(Supplementary Tables 2–4). The biological processes impli-
cated from the DAVID pathway analysis included cell develop-
ment, embryonic morphogenesis, development, regulation of
multicellular organismal processes, cell–cell signalling, embryonic
development, forebrain development and, notably, neural tube
development (Supplementary Table 2). Ingenuity Pathway
Analysis (IPA) results indicated pathways related to nervous
system development and function, cell–cell signalling and basic
developmental processes (Supplementary Table 3). Gene ontology
enrichment analysis and visualization tool results included
pathways related to the synaptic signalling, cell–cell signalling,
regulation of cAMP biosynthetic process, single-organism
behaviour, single-organism signalling, signalling, regulation of
gastrulation and the regulation of nervous system development
(Supplementary Table 4).
Methylation expression analysis. Of the 365 CpGs associated
with folate that we were able to match to a gene transcript
(±250 kb), 43 CpGs were signiﬁcantly associated with altered
expression of nearby genes (PBHo0.1). For most CpGs, increased
methylation was associated with decreased gene expression
(Supplementary Table 5).
Discussion
Our study is the largest to date using the Illumina 450K
epigenome-wide platform to evaluate the impact of maternal
plasma folate levels during pregnancy on DNA methylation in
newborns. We meta-analysed results from two population-based
birth cohort studies in Northern Europeans that measured DNA
methylation using the same platform. We observed epigenome-
wide FDR-signiﬁcant associations between maternal plasma folate
and DNA methylation in cord blood at 443 CpGs.
Table 2 | Selected loci with differential methylation in cord blood in relation to maternal folate.
CHR Position CpG Gene Gene
group
MoBa Generation R Meta-analysis
Coef s.e. P Coef s.e. P Weighted
mean beta
Coef s.e. P
7 126698829 cg15908975 GRM8 Body 0.012 0.003 8.26E06 0.015 0.007 2.46E02 0.54 0.012 0.002 6.76E07
7 126889015 cg18574254 GRM8 50-UTR 0.010 0.002 3.25E06 0.011 0.003 2.40E04 0.84 0.011 0.002 3.27E09
10 91296252 cg22591480 SLC16A12 TSS1500 0.009 0.002 1.96E04 0.008 0.003 2.33E02 0.85 0.008 0.002 1.34E05
10 91296311 cg14920044 SLC16A12 TSS1500 0.011 0.003 6.45E05 0.011 0.005 2.31E02 0.78 0.011 0.003 4.31E06
11 132951838 cg24829292 OPCML Body 0.008 0.003 9.45E03 0.014 0.004 7.55E05 0.44 0.010 0.002 6.60E06
11 132951861 cg22629528 OPCML Body 0.015 0.005 5.45E03 0.031 0.009 4.54E04 0.60 0.019 0.005 2.91E05
11 132951950 cg26283170 OPCML Body 0.006 0.002 9.46E03 0.015 0.004 4.58E05 0.54 0.009 0.002 1.30E05
12 49689685 cg24804179 PRPH Body 0.007 0.002 3.73E05 0.007 0.004 8.72E02 0.20 0.007 0.002 8.05E06
12 49690254 cg05775627 PRPH Body 0.006 0.002 3.61E03 0.007 0.002 7.87E04 0.63 0.007 0.002 1.01E05
12 49692283 cg16010628 PRPH 30-UTR 0.006 0.001 8.58E06 0.002 0.003 4.51E01 0.29 0.005 0.001 1.73E05
16 2866901 cg05635274 PRSS21 TSS1500 0.008 0.002 1.79E04 0.013 0.005 5.05E03 0.82 0.009 0.002 4.77E06
16 2867051 cg02296564 PRSS21 TSS200 0.011 0.003 7.43E04 0.011 0.004 2.63E03 0.64 0.011 0.003 6.21E06
16 2867434 cg22730830 PRSS21 Body 0.012 0.003 2.69E04 0.016 0.005 4.02E03 0.59 0.013 0.003 3.99E06
16 2867446 cg01232511 PRSS21 Body 0.012 0.004 9.50E04 0.020 0.006 2.32E03 0.67 0.014 0.003 1.23E05
17 35285205 cg10612259 LHX1 0.009 0.003 1.91E04 0.015 0.004 5.54E05 0.47 0.011 0.002 9.10E08
17 35285295 cg01965477 LHX1 0.002 0.001 5.26E04 0.003 0.001 8.80E03 0.06 0.002 0.001 2.09E05
19 1453909 cg11775595 APC2 Body 0.017 0.003 8.04E07 0.010 0.005 3.57E02 0.44 0.015 0.003 1.64E07
19 1456246 cg14907738 APC2 Body 0.006 0.001 3.59E05 0.005 0.003 9.34E02 0.22 0.006 0.001 8.57E06
19 1456337 cg27150178 APC2 Body 0.009 0.002 6.01E06 0.007 0.003 3.00E02 0.32 0.009 0.002 5.81E07
19 1456886 cg03165176 APC2 Body 0.012 0.003 1.96E04 0.012 0.005 2.62E02 0.58 0.012 0.003 1.44E05
19 1457211 cg14559388 APC2 Body 0.003 0.001 3.49E05 0.002 0.001 4.52E02 0.05 0.003 0.001 4.98E06
19 1465207 cg04624885 APC2 Body 0.016 0.003 3.08E07 0.003 0.003 4.43E01 0.66 0.010 0.002 1.56E05
19 1472936 cg19870717 APC2 30-UTR 0.010 0.002 1.81E08 0.006 0.003 4.46E02 0.37 0.009 0.002 4.64E09
19 1473042 cg16613938 APC2 30-UTR 0.017 0.003 1.15E07 0.011 0.006 7.00E02 0.71 0.016 0.003 3.05E08
19 1473179 cg23291200 APC2 30-UTR 0.011 0.002 7.81E08 0.008 0.003 3.92E03 0.63 0.010 0.002 1.72E09
19 51415450 cg13793157 KLK4 0.009 0.002 2.85E04 0.009 0.005 5.41E02 0.53 0.009 0.002 4.00E05
19 51415452 cg10078829 KLK4 0.007 0.002 1.89E04 0.007 0.003 3.57E02 0.40 0.007 0.002 1.84E05
CHR, chromosome; Coef, regression coefﬁcient from statistical model; gene, mapped or nearest gene (within 10Mb) symbol using the UCSC database and Snipper software; gene group, gene region
feature category (UCSC with veriﬁcation); P, uncorrected P value from statistical model; UTR, untranslated region; weighted mean beta, average of the mean methylation beta values for MoBa and
Generation R cohorts, weighted by cohort sample size.
Selection limited to genes with at least two CpGs at FDR signiﬁcance that were prioritized for discussion.
Meta-analysis of results for 1,275 MoBa participants and 713 Generation R participants. Robust linear regression models adjusted for maternal age, maternal education, maternal sustained smoking during
pregnancy, parity and batch. Results sorted by the chromosome and position of the CpG sites listed. For complete list of CpGs differentially methylated in relation to maternal folate and for results from
meta-analysis models unadjusted for covariates and adjusted for covariates and cell type see Supplementary Data 1 (sorted by P value) and 2 (sorted by chromosome, position). Supplementary Data
include columns for mapped and nearest gene for each CpG.
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It is notable that many of the implicated genes have functional
relevance to various developmental pathways. Some are relevant
to NTDs, the indication for maternal folic acid supplementation,
and others to distinct developmental conditions that have not
been previously associated with maternal folate levels. Additional
genes we identiﬁed have been implicated in conditions where
there is some concern about possible adverse effects of higher
folate levels, such as breast cancer progression16. Due to the large
number of genes signiﬁcantly differentially methylated in relation
to folate (Supplementary Data 1 and 2), we focus this discussion
primarily on genes with two or more CpGs at genome-wide
signiﬁcance after FDR correction (PBHo0.05) where at least one
CpG is within the gene (Table 2).
We observed the largest number (nine) of statistically
signiﬁcant CpGs mapping to the gene adenomatosis polyposis
coli 2 gene (APC2). APC2 is expressed in both human fetal and
adult brain17 and in the peripheral nervous system18. It plays a
critical role in the brain development in several model systems19.
APC2 may also play a role in cancer aetiology. A homologue of
the tumour suppressor gene APC20, APC2, is involved in the
regulation of the Wnt signalling pathway, which impacts both
normal development and tumorigenesis21. Studies in mice have
reported associations between periconceptional maternal folate
and methylation of APC genes22. In two human breast cancer
lines, folate leads to methylation-mediated silencing of APC and
other tumour suppressor genes, raising concern about the risk
of tumour progression23. Thus, folate-related methylation of
APC2 during fetal development could impact both pathways of
neurodevelopment and carcinogenesis.
GRM8 encodes a glutamate receptor that interacts with
L-glutamate, the major excitatory neurotransmitter in the central
nervous system. Glutamatergic neurotransmission is ubiquitous
in normal brain function24 and is perturbed in various
neuropathologies. In humans, copy-number variations of GRM8
have been associated with neurodevelopmental disorders such as
attention-deﬁcit hyperactivity disorder25 and autism spectrum
disorder26.
A number of genes we identiﬁed as differentially methylated in
newborns in relation to maternal folate are known to harbour
mutations that have been causally implicated in various develop-
mental abnormalities other than NTDs, the indication for folic acid
supplementation in pregnancy. These include several with two or
more statistically signiﬁcant CpGs (Table 2) such as SLC16A12,
implicated in juvenile cataracts with microcornea and renal
glucosuria27; and KLK4, implicated in the dental malformation
amelogenesis imperfecta28. Mutations in LHX1 have been
associated with abnormalities in uterine development29, and
recent evidence suggests an important role in retinal
development30. Several genes with one CpG at genome-wide
statistical signiﬁcance (Supplementary Data 1 and 2) also harbour
mutations that are causal for various development malformations.
These include IHH involved in skeletal malformations, ROBO3
involved in horizontal gaze palsy with progressive scoliosis, PCSK9
involved in familial hypercholesterolemia, FAM83H related to
amelogenesis imperfecta type 3 and GJA3 associated with
congenital cataracts. Taken together, these ﬁndings suggest a role
for periconceptional folate levels in birth defects not previously
known to be related to this nutrient.
Our agnostic evaluation of maternal folate levels and DNA
methylation in newborns also identiﬁed genes related to various
neurologic diseases. Genetic variation in OPCML and PRPH has
been associated with the neurodegenerative disease amyotrophic
lateral sclerosis31,32. In genome-wide association studies, CSMD1
has been associated with schizophrenia and autism33.
Some previous studies of folate and methylation have examined
the H19 imprinted region11,34. We identiﬁed three signiﬁcant CpGs
located 45–48-Kb upstream of H19 among 77 CpGs on the platform
that are within 48 up- or downstream of H19.
The largest number of statistically signiﬁcant associations at
any locus, 31, are on chromosome 12 and, based on our extended
annotation, are nearest to ALG10. Two CpGs are 262–573-kb
upstream; the other 29 CpGs are 261–573-kb downstream. None
are in ALG10. Most are in a CpG island near the centromere and
there are no features that suggest functional impact.
In the only previous study using the 450K platform,
Amarasekera et al12 reported differential methylation in relation
to maternal folate in a 923-bp region on chromosome 6, 3-kb
upstream of ZFP57. Our studies differ in sample sizes, design and
analysis methods. However, when we evaluate the 20 CpGs that
map to ZFP57, we ﬁnd 5 with uncorrected P values of 0.05 or
smaller—more than would be expected by chance alone. Thus,
our data provide support for association at this locus.
From correlation analysis of 450K methylation data and gene
expression in white blood cells in adults, after correction for
multiple testing, 43 CpGs that we implicated in relation to
maternal folate were also related to expression of nearby genes
(Supplementary Table 5). Although correlation of 450K methyla-
tion with gene expression in the same newborn samples would
have been preferable, we were only able to examine correlations
in a population of Dutch adults. The most statistically signiﬁcant
correlation between methylation and gene expression was
observed for the gene PRSS21 (protease serine 21 (testisin)); four
CpGs were both signiﬁcantly associated with maternal folate
(Table 2) and expression of this gene (Supplementary Table 5).
PRSS21 is a tumour suppressor gene silenced by aberrant
methylation in testicular germ cell tumours35. Testicular germ
cell tumours are diagnosed in early adulthood and can manifest
as early as 15 years of age. Prenatal origin of this tumour has been
proposed36; perhaps, methylation in utero, inﬂuenced by
maternal folate levels, could play a role in this pathogenesis.
Because other important factors in one-carbon metabolism
could potentially explain associations between folate levels and
DNA methylation in cord blood, we performed various sensitivity
analyses (Supplementary Data 3). On the basis of these analyses,
vitamin B12 does not confound the folate–methylation associa-
tion. This lack of confounding by B12 should extend to other B
vitamins such as B6 and riboﬂavin that are present in
multivitamins along with B12. We did not have data in both
studies on choline, a nutrient that can serve as a source of
one-carbon units. However, in MoBa, where choline was
measured, there was no correlation with folate levels (Spearman
correlation¼  0.034, P¼ 0.23) and thus choline should not
confound associations between folate and methylation. Vitamin
D is not part of the one-carbon metabolism cycle but might
impact methylation by other mechanisms37. We performed
analyses in a subsample taking vitamin D into account as proxy
for intake of other supplements or possibly healthy dietary
patterns and observed no major differences in results. Adjustment
of the folate–methylation association for homocysteine, a product
formed in one-carbon metabolism that is itself an excellent
marker of folate status, resulted in a substantial reduction in the
number of statistically signiﬁcant ﬁndings. Although caution is
required, both because folate and homocysteine are correlated,
and because they operate together in a cycle rather than a clear
unidirectional pathway, this attenuation could be interpreted as
homocysteine, at least in part, mediating some of the associations
between folate and methylation.
Given the role of folate as a major provider of methyl groups in
the one-carbon metabolism pathway, our ﬁnding of reduced
methylation with higher folate at the majority of the implicated
CpGs may seem counterintuitive. However, methyl groups from
the one-carbon metabolism pathway are used in a range of
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biological processes and the complex interactions of these systems
may not necessarily result in linear relationships. Indeed, there is
evidence that effects of folate on folate-dependent enzymes may
switch directions at the higher intracellular concentrations that
may accompany folic acid supplementation38. Folic acid, in
vitamin supplements or food fortiﬁcation, is a synthetic folate
with possible effects that differ from those of natural occurring
folate species. There is recent evidence that folic acid interferes
with the inhibitory effect of S-adenosylmethionine (SAM) on
methylenetetrahydrofolate reductase (MTHFR)39 and may inhibit
MTHFR activity, thereby reducing the amount of 5-methyl-
tetrahydrofolate, SAM and the SAM/S-adenosylhomocysteine
(SAH) ratio40. The SAM/SAH ratio has been referred to as the
methylation potential; low SAM/SAH ratio may decrease DNA
methylation. This may explain the inverse relationship we observe
in our study but additional research is needed to more fully
explain the complex biochemistry behind these observations. Of
note, inverse correlations between prenatal folate status and DNA
methylation at differentially methylated loci have been identiﬁed
in the other population studies including Hoyo et al.34 and
Amarasekera et al.12
Although the health outcomes that have been related to folic
acid supplementation involve target tissues such as the nervous
system, we only had cord blood available for assessment of
methylation. We do not know whether differential methylation at
the sites that we observed in cord blood would be observed in
relevant target tissues. While divergence in epigenetic patterns is
critical for cell-type regulation, there is also evidence of
similarities in patterns among some tissues41–43. We do not
have data on methylation at older ages and thus the question of
whether the differential methylation at these loci seen at birth in
relation to maternal folate persists to later childhood would need
to be addressed in future studies.
We measured folate using two different platforms in the two
studies. Both are valid methods for the measurements of folate.
Levels were reasonably similar although slightly higher in
Generation R, which could reﬂect a difference in the platforms,
differences in folate intake or the earlier timing of measurements
in Generation R (B12-week gestation in Generation R versus
B18-week gestation in MoBa). Nonetheless, the top ﬁndings
were consistent in both cohorts and thus robust to differences in
measurement platforms. This may increase their generalizability
to other populations.
One-carbon metabolism is a complex pathway with inﬂuences
from multiple genetic, hormonal and environmental factors.
Despite our attempt to account for other important dietary intake
involved in one-carbon metabolism, other supplementation and
genetic variants, residual confounding could still be present and
inﬂuence the observed associations of folate levels in pregnancy
with methylation at birth.
The MoBa and Generation R cohorts offer a unique
opportunity to study the epigenetic effect of folic acid supple-
mentation in the absence of food supply fortiﬁcation. It is possible
that results may differ in populations exposed to fortiﬁcation.
We identiﬁed multiple novel genes not previously implicated in
biological responses to folate. Many of the implicated genes have
functional relevance to various developmental pathways, includ-
ing the nervous system. Some of these are relevant not only to
NTDs, the indication for maternal folic acid supplementation, but
also to other developmental abnormalities that have not been
previously associated with maternal folate levels. The associations
between periconceptional folate and these conditions are
difﬁcult to study because the abnormalities are rare and both
supplementation and fortiﬁcation are now widespread. Other
genes identiﬁed are implicated in conditions where concern exists
about possible adverse effects of higher folate levels, such as breast
cancer progression16. These ﬁndings may provide new insights
into mechanisms for the associations between maternal folate
status and health outcomes in the offspring. Given that food
fortiﬁcation programs have greatly increased the folate status of
the population, greater understanding of the biological effects of
this nutrient is important. The large number of novel genes
identiﬁed using our genome-wide methylation approach may
shed light on the protean effects of folate on human health.
Methods
Study populations. This analysis included participants of the Norwegian Mother
and Child Cohort Study (MoBa)44,45 and participants of the Generation R Study
from the Netherlands. The study populations and cohort-speciﬁc methods
described below are more extensively detailed in the Supplementary Information
(Supplementary Note). The MoBa participants were mother–offspring pairs from a
substudy measuring maternal plasma folate during pregnancy46. The Generation R
Study is a population-based prospective cohort study from fetal life onwards47,48.
For this analysis, information on plasma folate and DNA methylation was available
for 1,289 mothers and their children from the MoBa study (1,275 with complete
covariate data) and 790 Caucasian mothers, and their children from the Generation
R Study (713 with complete covariate data).
The MoBa study was approved by the Regional Committee for Ethics in
Medical Research, the Norwegian Data Inspectorate and the Institutional Review
Board of the National Institute of Environmental Health Sciences, USA, and
written informed consent was provided by all mothers participating. The
Generation R Study has been approved by the Medical Ethical Committee of the
Erasmus MC, University Medical Center Rotterdam, Netherlands and written
consent was obtained from participating parents of their children.
Maternal plasma folate measurements. Both cohorts measured maternal plasma
folate during pregnancy. For MoBa, maternal blood samples were drawn during
pregnancy (median weeks gestation¼ 18 weeks, 25–75th percentile¼ 16–21 weeks)
in EDTA-lined tubes, centrifuged within 30min after collection and stored at 4 C
in the hospital where they were collected. Samples were then shipped overnight to
the Biobank of MoBa at the Norwegian Institute of Public Health in Oslo. Upon
receipt (1–2 days after blood collection), plasma was aliquoted onto polypropylene
microtiter plates, sealed with heat-sealing foil sheets and stored at  80 C.
Plasma folate concentration was measured at Bevital AS (www.bevital.no) by
microbiological assay, using a chloramphenicol-resistant strain of Lactobacillus
casei49, which measures biologically active folate species, predominantly 5-methyl-
tetrahydrofolate. The coefﬁcient of variation (CV) for this assay corresponds to 4%
within day and 5% between days, at population median.
For the Generation R cohort, venous blood samples were drawn at enrolment of
the mothers in early pregnancy (median weeks gestation¼ 12.9 weeks; 25–75th
percentile¼ 12.1–13.9 weeks) and stored at room temperature for a maximum of
3 h. Samples were transported to a laboratory facility of the regional laboratory in
Rotterdam, Netherlands (Star-Medisch Diagnostisch Centrum) for additional
processing and storage at  80 C. The samples were analysed at the
Department of Clinical Chemistry at the Erasmus MC, University Medical Center
Rotterdam, Netherlands. After thawing, folate concentrations were analysed using
an immunoelectrochemoluminence assay on the Architect System (Abbott
Diagnostics BV). Between-run CVs for plasma measurements were 8.9% at
5.6 nmol l 1, 2.5% at 16.6 nmol l 1 and 1.5% at 33.6 nmol l 1 with an analytic
range of 1.8–45.3 nmol l 1 for plasma folate.
Covariates. Each cohort had information on maternal age, education and parity
from questionnaires completed by the mother or from birth registry records.
Maternal smoking during pregnancy was ascertained with questionnaires (both
cohorts) and cotinine levels (MoBa). Plasma levels of vitamin B12, vitamin D and
total homocysteine from samples taken during pregnancy were available for both
cohorts. Mothers in both cohorts were genotyped for two SNPs in the (NAD(P)H)
MTHFR gene, rs1801131 and rs1801133. Additional detail on these measurements
is in the Supplementary Information (Supplementary Note).
DNA methylation measurements. DNA was extracted from cord blood and
bisulﬁte conversion performed (EZ-96 DNA Methylation kit, Zymo Research
Corporation, Irvine, USA). Samples were processed with Illumina’s Inﬁnium
HumanMethylation450 BeadChip (Illumina Inc., San Diego, USA) followed by
cohort-speciﬁc laboratory quality control. Each cohort calculated the methylation
betas, and normalized the betas using a published method50,51.
Estimation of cell-type proportions. Both the MoBa and Generation R studies
estimated cell-type proportion with the Houseman method52 as implemented in
the R minﬁ package53 using the Reinius et al. data set for reference54. Cell-type
correction was applied by including the six estimated cell-type proportions as
covariates in cohort-speciﬁc statistical models.
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Cohort-speciﬁc statistical analyses. The cohort-speciﬁc statistical models were
run independently. For each cohort, we used robust linear regression models in R55
to evaluate the association between natural log-transformed maternal plasma folate
and cord blood DNA methylation for each probe while accounting for potential
heteroskedasticity and/or inﬂuential outliers. Models were adjusted for maternal
age, education, smoking during pregnancy, parity and for batch effects (adjustment
for plate in Generation R, correction using ComBat50 in MoBa). Additional
correction for study design was done in MoBa (whether the participant was in the
MoBa1 or MoBa2 data set). Sex of the child was not expected to be associated with
maternal plasma folate and was therefore not included as a covariate in the
analyses. The adjustment variables were selected on a priori considerations and
because they were also associated with maternal plasma folate levels at Po0.05.
Meta-analysis. The probe-speciﬁc quality control resulted in 473,731 CpGs in the
MoBa cohort and 436,013 CpGs in the Generation R cohort. The meta-analysis was
limited to the 425,749 CpGs common to both cohorts. An additional 5,844 CpGs
were excluded for having a SNP mapping to the last ﬁve nucleotides of the probe
sequence and with a minor allele frequencyX5% in the CEU (Utah residents with
North and Western European ancestry) population, curated by 1000G projects
(http://www.1000genomes.org/, 06/2011 release, 87 individuals), HapMap project
(http://hapmap.ncbi.nlm.nih.gov/, release 28, 8/2010, 174 individuals) and dbSNP
(http://www.ncbi.nlm.nih.gov/projects/SNP/, build 134, 8/2011, 116 individuals).
This left 419,905 CpGs for the ﬁnal meta-analyses.
Fixed-effect meta-analysis weighted by the inverse of the variance was completed
using METAL56. Multiple testing was accounted for by using the FDR procedure by
Benjamini and Hochberg (BH)57. For each CpG, the resulting BH corrected P values
are denoted by PBH. CpGs with PBHo0.05 were considered statistically signiﬁcant.
CpGs that were statistically signiﬁcant based on the more stringent Bonferroni
correction (uncorrected Po1.19 10 7 to account for 419,905 tests) were noted. We
present the covariate-adjusted model without cell-type adjustment as the primary
results. In the Supplementary Information, we present results additionally adjusted for
cell type and results without covariate adjustment.
Sensitivity analyses. We performed sensitivity analyses to assess whether the
associations observed between folate and methylation might be explained by levels
of vitamin B12, a dietary co-factor involved in regulating carbon unit bioavail-
ability. Vitamin B12 is generally present in multivitamins that pregnant women in
our studies may have taken in addition to, or in lieu of, separate folic acid
supplements. Multivitamin supplements containing B12 typically contain other B
vitamins including vitamin B6, which is also involved in one-carbon metabolism.
Because mothers with higher folate levels may have higher intakes of other vitamin
supplements not involved in the one-carbon metabolism pathway, or healthier
diets in general, we also performed separate analyses adjusting for maternal plasma
vitamin D levels during pregnancy. We also examined two SNPs in MTHFR
involved in modulation of one-carbon metabolism: rs1801131 and rs1801133
(refs 14,15). We evaluated the impact of adjustment for total homocysteine on the
association between maternal plasma folate and DNA methylation in newborns.
Finally, we examined whether the associations with methylation seen for maternal
folate levels are also seen for newborn folate levels in a subset of 572 subjects in
Generation R.
Pathway analysis. To better understand the functional relationships between dif-
ferentially methylated CpGs, we evaluated the FDR-signiﬁcant CpGs with pathway
analysis using three independent software programs. First, gene ontology analysis was
performed using the IPA (www.ingenuity.com) based on the content version of
21249400 (release date: 22 September 2014). For a given category in IPA, Fisher’s exact
test was used to measure the probability that the category was randomly associated
(Po0.05 deﬁned as signiﬁcantly enriched). Second, the NIAID’s DAVID Bioinfor-
matics Resources 6.7 (ref. 58) was used to analyse enrichments in main categories:
biological process, cellular component, molecular function and KEGG pathway. Third,
we used gene ontology enrichment analysis and visualization tool59 to identify the
most informative terms that are signiﬁcantly enriched.
Methylation expression analysis. We evaluated the association between
methylation and quantitative levels of gene expression for our top CpGs. We used
messenger RNA gene expression and 450K methylation data both from white
blood cells from adults over 45 years of age in the Rotterdam Study, a population-
based prospective cohort study in Rotterdam, the Netherlands. Among the 443
FDR-signiﬁcant CpGs associated with folate, we were able to match 365 CpGs to a
gene transcript in our gene expression data set within a region of 250-kb upstream
or downstream of the CpG (total region 500 kb). We analysed the associations of
these CpGs with expression levels of the corresponding gene transcripts.
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